Idhentify nct02577406
WebAcute myeloid leukemia (AML) be to most common form of acuteness leukemia in adults, with einer incidence that increases with age, and ampere generally poor outlook. The virus is clinically and genetically heterogeneous, and recent forward may improved our understanding of this cytogenetic abnormalities or moln mutations, helped the … WebIDHENTIFY (NCT02577406) is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs), which include continuous 28-day cycles of best supportive care (BSC) only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine SC plus BSC, or …
Idhentify nct02577406
Did you know?
WebNCT02577406 An Efficacy and Safety Study of AG-221 (CC-90007) versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY) Recruiting III NCT02632708 Safety Study of AG-120 or AG-221 in Combination with Induction and Consolidation Therapy in … Web24 apr. 2024 · On 1 March, the FDA accepted Celgene and Agios’s New Drug Application (NDA) for the IDH2 inhibitor enasidenib (AG-221/CC-90007) for the treatment of patients with relapsed/refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH2) mutation.
Web1 jun. 2024 · Methods: This open-label trial (NCT02577406) enrolled pts ≥ 60 years of age who had received 2 or 3 prior AML Tx. Pts were preselected to a CCR (azacitidine, intermediate- or low-dose Ara-C, or... Web1 okt. 2024 · Methods: IDHENTIFY (NCT02577406) enrolled patients aged 60 years who had received 2-3 prior AML-directed therapies. Patients were randomized 1:1 to …
WebKurztitel AG-221-AML-004 (IDHentify) Studienart multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, zweiarmig Studienphase Phase III ... ClinicalTrials.gov NCT02577406 EudraCT 2015-000344-42 Links Studiendokumente zum Download (roXtra) 1 WebEnjoy a 7-Day Free Trial Thru Apr 15, 2024! . Sign Up. Login
Web17 mei 2024 · There is one phase 3 randomized, open-label study comparing Enasidenib to conventional care specifically in patients age 60 or older with relapsed/refractory IDH2-mutant advanced AML, also known as IDHENTIFY (ClinicalTrials.gov NCT02577406). The IDHENTIFY protocol was presented at the 2024 American Society of Clinical Oncology …
Web20 mei 2016 · The international IDH ENTIFY study (NCT02577406) in pts with m IDH2 + AML is the first randomized trial to evaluate an AML Tx in older pts R/R to multiple prior Tx courses—a pt population with few Tx options. Methods: Eligible pts are age ≥60 years with primary or secondary m IDH2 + AML and R/R after 2 or 3 prior Tx regimens. risk optimizationWeb27 aug. 2024 · IDHENTIFY or NCT02577406 is an international, multicenter, open-label, randomized, Phase 3 study. It is designed to compare the efficacy and safety of AG-221 versus conventional care regimens in ... risk management program goalsWebMethods: This open-label trial (NCT02577406) enrolled pts ≥ 60 years of age who had received 2 or 3 prior AML Tx. Pts were preselected to a CCR (azacitidine, intermediate- or low-dose Ara-C, or supportive care), and were then randomized 1:1 to ENA 100 mg/d or CCR in 28d cycles. riskrem rema 1000Web25 aug. 2024 · This is the result of data from the phase 3 IDHENTIFY study (NCT02577406), which was negative for its primary end point, announced Bristol Myers … risondrugWebH&O What is the mechanism of action of enasidenib?. GR Enasidenib (Idhifa, Celgene/Agios) is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzymes.IDH2 mutations occur in approximately 15% of patients with acute myeloid leukemia (AML). The mutant proteins catalyze production of the oncometabolite 2 … ristikko ratkojatWeb1 okt. 2024 · Methods: IDHENTIFY (NCT02577406) enrolled patients aged ≥60 years who had received 2-3 prior AML-directed therapies. Patients were randomized 1:1 to enasidenib 100-mg/day or CCR (azacitidine, intermediate- or low-dose Ara-C, or supportive care). Co-occurring mutations were identified by targeted NGS of BMMC DNA. ristoja pdfWeb1 mrt. 2024 · Celgene is also evaluating enasidenib compared with conventional therapy in older patients with an IDH2 mutation and relapsed or refractory AML in the ongoing phase III IDHENTIFY trial (NCT02577406). Enasidenib is an investigational drug that has not been approved for any use in any country. ristoranti zairo padua menu